These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8406417)

  • 1. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues.
    Colgan TJ; Pendergast S; LeBlanc M
    Hum Pathol; 1993 Oct; 24(10):1073-7. PubMed ID: 8406417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological changes of uterine leiomyomas after GnRH agonist therapy.
    Grigoriadis C; Papaconstantinou E; Mellou A; Hassiakos D; Liapis A; Kondi-Pafiti A
    Clin Exp Obstet Gynecol; 2012; 39(2):191-4. PubMed ID: 22905461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents].
    Resta L; Sanguedolce F; Orsini G; Laricchia L; Piscitelli D; Fiore MG
    Pathologica; 2004 Apr; 96(2):35-41. PubMed ID: 15449444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GnRH analogue-induced uterine shrinkage enabling a vaginal hysterectomy and repair in large leiomyomatous uteri.
    Schneider D; Golan A; Bukovsky I; Pansky M; Caspi E
    Obstet Gynecol; 1991 Sep; 78(3 Pt 2):540-1. PubMed ID: 1831252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas.
    Stovall TG; Ling FW; Henry LC; Woodruff MR
    Am J Obstet Gynecol; 1991 Jun; 164(6 Pt 1):1420-3; discussion 1423-5. PubMed ID: 1904681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
    Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
    Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
    Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
    Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas.
    Yoshida M; Ohtsuru A; Samejima T; Okazaki M; Fujishita A; Ito M; Yamashita S; Ishimaru T
    Endocr J; 1999 Feb; 46(1):81-90. PubMed ID: 10426571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
    Friedman AJ; Lobel SM; Rein MS; Barbieri RL
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preoperative treatment with GnRH analogs in hysterectomy].
    Serrao L; Brizzi C; Primiero FM
    Clin Ter; 1994 Nov; 145(11):403-6. PubMed ID: 7889725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GnRH agonists before surgery for uterine leiomyomas. A review.
    Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
    J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of uterine fibroids with GnRH-analogues prior to hysterectomy.
    Stjernquist M
    Acta Obstet Gynecol Scand Suppl; 1997; 164():94-7. PubMed ID: 9225649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy.
    Khurana KK; Singh SB; Tatum AH; Schulz V; Badawy SZ
    J Reprod Med; 1999 Jun; 44(6):487-92. PubMed ID: 10394541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
    Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
    Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
    Lethaby A; Vollenhoven B; Sowter M
    Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
    Lethaby A; Vollenhoven B; Sowter M
    Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal therapy before surgical treatment for uterine leiomyomas.
    Moghissi KS
    Surg Gynecol Obstet; 1991 Jun; 172(6):497-502. PubMed ID: 1827931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
    Takahashi K; Kawamura N; Ishiko O; Ogita S
    Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of uterine leiomyomas.
    Vilos GA; Allaire C; Laberge PY; Leyland N;
    J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix.
    Flierman PA; Oberyé JJ; van der Hulst VP; de Blok S
    BJOG; 2005 May; 112(5):638-42. PubMed ID: 15842290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.